Helminths (including anthelmintic resistance) roadmap:
Therapeutics
Roadmap for development of therapeutics for helminths
Download Helminths-Therapeutic-Tests-Roadmap
---
config:
theme: default
defaultRenderer: 'elk'
themeVariables:
lineColor: "red"
---
flowchart LR
22312["
2
Clinical testing- AEfficacy
- BQuality
1
Therapeutics3
Risk assessment methodologies- ATarget animal
- BUser
- CResidues
- DEnvironmental
1
Therapeutics4
Minimum Viable Product Profile2
Clinical testing- AEfficacy
- BQuality
4
Minimum Viable Product Profile3
Risk assessment methodologies- ATarget animal
- BUser
- CResidues
- DEnvironmental
5
Pharmacology"] --> 22326["4
Minimum Viable Product Profile6
Repurposing of medicines5
Pharmacology"] 22329["7
Alternatives to animal testing"] --> 22312["2
Clinical testing- AEfficacy
- BQuality
7
Alternatives to animal testing"] --> 22325["3
Risk assessment methodologies- ATarget animal
- BUser
- CResidues
- DEnvironmental
7
Alternatives to animal testing"] --> 22327["5
Pharmacology"] 22329["7
Alternatives to animal testing"] --> 22330["8
Animal models8
Animal models5
Pharmacology"] 22331["9
Mode of action/Resistance5
Pharmacology"] 22331["9
Mode of action/Resistance11
Target Identification- APhenotypic
- BMechanism-based
9
Mode of action/Resistance10
Test for drug resistance- AClinical
- BGenetic
11
Target Identification- APhenotypic
- BMechanism-based
8
Animal models11
Target Identification- APhenotypic
- BMechanism-based
9
Mode of action/Resistance12
Compound libraries11
Target Identification- APhenotypic
- BMechanism-based
13
Host pathogen interactions- AEntry
- BReplication
- CSurvival
- DCoinfection
11
Target Identification- APhenotypic
- BMechanism-based
14
Pathogen physiology/biochemistry13
Host pathogen interactions- AEntry
- BReplication
- CSurvival
- DCoinfection
Lead Summary | Challenges and gap analysis | |
---|---|---|
1 | Therapeutics | Improved therapeutic response against helminth parasites in ruminants |
2B | Quality | |
2A | Efficacy | |
2 | Clinical testing | Clinical efficacy, quality and safety assessments for a novel API with anthelmintic activity |
3D | Environmental | |
3C | Residues | |
3B | User | |
3A | Target animal | |
3 | Risk assessment methodologies | |
4 | Minimum Viable Product Profile | |
5D | Formulation delivery routes | Pharmacology: Formulation, delivery routes |
5C | Combination of drugs/API | Pharmacology: Combination of drugs/API |
5B | PK/PD integration | Pharmacology: PK/PD integration |
5A | Drug design | Pharmacological basis to design a novel anthelmintic molecule |
5 | Pharmacology | |
6 | Repurposing of medicines | Drug repurposing |
7C | Refine | |
7B | Reduce | Alternative to Animal Testing – Reduce, Refine |
7A | Replace | Alternative to Animal Testing - Replace |
7 | Alternatives to animal testing | |
8 | Animal models | Animal models |
9 | Mode of action/Resistance | Mode of action/Resistance |
10B | Genetic | |
10A | Clinical | |
10 | Test for drug resistance | Detection of drug resistance: clinical and genetic tests |
11B | Mechanism-based | |
11A | Phenotypic | |
11 | Target Identification | Target Identification |
12 | Compound libraries | Compound libraries |
13D | Coinfection | |
13C | Survival | |
13B | Replication | |
13A | Entry | |
13 | Host pathogen interactions | How do host and parasites interact?: Entry, survival and co-infection |
14 | Pathogen physiology/biochemistry | Further knowledge on parasite physiology/biochemistry |